Please login to the form below

Not currently logged in


This page shows the latest contraception news and features for those working in and with pharma, biotech and healthcare.

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

Finally, the panel recommended that Novartis’ multiple sclerosis drug Gilenya (fingolimod) should not be used in pregnant women and in women able to have children who are not using effective contraception

Latest news

More from news
Approximately 10 fully matching, plus 62 partially matching documents found.

Latest Intelligence

  • Immunisation politicised Immunisation politicised

    contraception research and development.

  • The pill branding The pill branding

    In Eastern Europe and Belarus, the positioning rather targets the topic of escape, and in Latin American countries, the brands focus on the very neutral topic of contraception. ... Naming and branding recommendations. Drawing on a branding study we

  • Designing unique patient solutions in rare disease Designing unique patient solutions in rare disease

    She has worked across a range of therapy areas including Psoriasis, Oral Contraception and MS.

  • Pharma deals during June 2013 Pharma deals during June 2013

    Bayer closed its acquisition of Conceptus, securing access to Essure, a non-surgical method of birth control, which extends Bayer's franchise in contraception.  .

  • Pharma deals during January 2013 Pharma deals during January 2013

    This acquisition brings with it an IUD for long term contraception (pending approval in Europe and phase III in the US) and Daifert an immunoassay kit for in vitro fertilisation. ... Acquisition. Contraception fertility. 305. Syncona / Wellcome Trust .

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....